See the DrugPatentWatch profile for Methylnaltrexone
Methylnaltrexone bromide is a medication used to treat opioid-induced constipation (OIC) in adults who have chronic non-cancer pain [1]. It is a peripherally acting mu-opioid receptor antagonist (PAMORA) [2].
How does methylnaltrexone bromide work?
Methylnaltrexone bromide works by blocking the effects of opioids on the mu-opioid receptors in the gastrointestinal tract [2]. Opioids can slow down bowel movements, leading to constipation. By blocking these receptors, methylnaltrexone bromide helps to restore normal bowel function without interfering with the pain-relieving effects of opioids in the central nervous system [2].
What are the different formulations of methylnaltrexone bromide?
Methylnaltrexone bromide is available in two formulations: an injectable solution and an oral tablet [1]. The injectable form is administered subcutaneously, typically every other day as needed [1]. The oral tablet is taken daily for OIC associated with chronic non-cancer pain [1].
When does methylnaltrexone bromide's patent exclusivity expire?
Patent exclusivity for methylnaltrexone bromide is a complex area influenced by multiple patents and potential legal challenges. Information on specific patent expiry dates and their implications for generic entry can be found on DrugPatentWatch.com [3].
What are the risks and side effects of methylnaltrexone bromide?
The most common side effects of methylnaltrexone bromide include abdominal pain, diarrhea, nausea, vomiting, and dizziness [1]. In rare cases, it can cause a sudden, severe bowel movement, which may be a sign of gastrointestinal perforation, a serious medical emergency [1]. Patients with a known or suspected blockage in their bowel should not take methylnaltrexone bromide [1].
How does methylnaltrexone bromide compare to other treatments for OIC?
Other PAMORAs like naloxegol and naldemedine are also used to treat OIC [2]. Methylnaltrexone bromide's efficacy and safety profile are evaluated against these and other treatment options when considering the best approach for a patient [2].
What clinical data supports the use of methylnaltrexone bromide?
Clinical trials have demonstrated that methylnaltrexone bromide can significantly increase bowel movements in patients with OIC [1]. These studies have assessed its effectiveness in achieving a bowel movement within a specified timeframe and its impact on patient-reported outcomes [1].
What is the pricing of methylnaltrexone bromide?
Pricing for methylnaltrexone bromide can vary based on formulation, dosage, insurance coverage, and pharmacy [4]. Information on specific costs and potential assistance programs may be available through the manufacturer or patient support services [4].
Who manufactures methylnaltrexone bromide?
Methylnaltrexone bromide is manufactured by Baxter International Inc. [5].
*
**Sources:
[1] https://www.drugpatentwatch.com/drug/methylnaltrexone-bromide
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/methylnaltrexone-bromide-patent-expiry
[4] https://www.drugpatentwatch.com/methylnaltrexone-bromide-price
[5] https://www.drugpatentwatch.com/methylnaltrexone-bromide-manufacturer